Notable Buzzers: Questcor Pharmaceuticals, Omeros Corporation, BioCryst Pharmaceuticals, Baidu Incadmin
New York, December 18, 2013 / Accesswire / — Market Buzz Report, which provides live alerts on penny stocks, issues critical stocks analysis for Questcor Pharmaceuticals Inc (NASDAQ:QCOR), Omeros Corporation (OMER), BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX), Baidu Inc (ADR) (NASDAQ:BIDU).
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) shares decreased 3.90% to $52 in the pre-market hour. The company on Dec. 17 announced that it has made a $25,000 donation to the Children’s Hospital & Research Center Oakland in support of the Early Intervention Services program.
Additionally, the company on Dec. 11 announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about January 24, 2014 to shareholders of record at the close of business on January 17, 2014. The Company also announced today that it made open market purchases during the fourth quarter of 2013 of approximately 500,000 shares of Questcor common stock through December 10, 2013. The shares were purchased at an average price of $57.21 per share.
Free Urgent Insider Catalyst Report For QCOR Available Here: http://marketbuzzreport.com/index.php?code=QCOR (Or Copy and paste the URL into your browser)
Omeros Corporation (OMER) shares gained 8.74% to $9.70 in the pre-market hour. The company on Dec. 18 announced that OMS721, the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for prevention of complement-mediated thrombotic microangiopathies (TMAs).
TMAs, including atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, are a family of rare, debilitating and life-threatening disorders characterized by multiple thrombi (clots) in the microcirculation of the body’s organs, most commonly the kidney and brain.
Free Urgent Insider Catalyst Report For OMER Available Here: http://marketbuzzreport.com/index.php?code=OMER (Or Copy and paste the URL into your browser)
BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX) shares gained 6.47% to $6.91 in the pre-market hour. The company on Dec. 18 announced that it has selected two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the prevention of hereditary angioedema (HAE) attacks.
The second generation discovery program’s goals of improving selectivity and bioavailability compared to BCX4161 were both met, with no effect on prothrombin time at high concentrations (>50 micromolar), and oral fraction absorbed exceeding 25%. Similar to BCX4161, these BioCryst discovered compounds demonstrate sub-nanomolar potency on the isolated enzyme and single digit nanomolar potency in suppressing kallikrein activity in an ex vivo activated human plasma kallikrein inhibition (aPKI) assay.
Free Urgent Insider Catalyst Report For BCRX Available Here: http://marketbuzzreport.com/index.php?code=BCRX (Or Copy and paste the URL into your browser)
Baidu Inc (ADR) (NASDAQ:BIDU) shares gained 0.81% to $169.69 in the pre-market hour. The company on Dec. 16 has announced the release of version 3.0 of its Baidu Browser Android app in 11 languages worldwide. In addition to support for multiple languages, Baidu Browser includes a customizable content dashboard that delivers news and photos directly to users’ homepages, as well as its proprietary T5 engine that speeds up page rendering by 30 percent. Since its December 2012 launch in China and Southeast Asia, Baidu Browser has gained more than 150 million users worldwide.
Additionally, Baidu’s Robin Li is Now the Richest Man in China. Robin Li, the man who beat Google (GOOG) in China, is now the country’s richest person, according to the Bloomberg Billionaires Index. Li’s net worth has increased $4.8 billion this year to over $12.2 billion, putting Li ahead of the former No. 1, Dalian Wanda Group chairman Wang Jianlin. Just two weeks ago, Li claimed the No. 2 spot.
Free Urgent Insider Catalyst Report For BIDU Available Here: http://marketbuzzreport.com/index.php?code=BIDU (Or Copy and paste the URL into your browser)
USMarketBuzz.com is an investment community that Focuses on MicroCap Securities. USMarketBuzz.com is an authorative authentic Google News Site and Leading Provider of Investment Awareness and Featured Company Profiles. If you would like more information regarding our news coverage solutions, please visit http://www.USMarketBuzz.com/ for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.USMarketBuzz.com/. Follow us on Facebook: https://www.facebook.com/usmarket.buzz Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PREPROMO to 27126. (SMS alerts are free, however data rates may apply, check your wireless plan for details.)
Posted: December 18th, 2013 under ACCESSWIRE.